Diagnostiskt Centrum Hud (‘DCH’), the leading provider of medical dermatology services in Sweden, has partnered with Bridgepoint Growth to further support the company’s expansion.

Headquartered in Stockholm, DCH was founded in 2012 by its CEO and three dermatologists, combining their business and medical backgrounds to address the untapped demand for high quality medical dermatology treatments. The market is underpinned by structural growth drivers, including an aging population and an increase in the incidence of skin diseases such as skin cancer. s. DCH focuses on treating melanoma, psoriasis and other severe dermatology conditions.

Today DCH operates six clinics across four Swedish cities and is the clear market leader in Sweden. DCH is a high-quality platform well placed for future growth in the fragmented dermatology markets across Northern Europe.

“We are excited to partner with Bridgepoint in the next stage of our expansion and further build the best dermatology provider across the Nordics together with our colleagues,“ said Philip Jerlmyr, CEO DCH.

”We are very impressed by DCH’s successful expansion to-date creating the leading dermatology provider focused on clinical excellence and high customer satisfaction thanks to its having the best dermatologists. We look forward to supporting the DCH team in its next phase of expansion” added Ann Dahlman, partner at Bridgepoint Growth responsible for its investment activities in the Nordic region.

Advisors involved in the transaction were:

For Bridgepoint: Vinge (legal), KPMG (financial and tax), Roland Berger (commercial)

For management: AG Advokat (legal), GT (financial and tax)